CLINFIL 300MG INJECTION (Clindsmycin USP 300mg/2ml)

Indications

• Skin and soft tissue infections
• Bone and joint infections
• Respiratory tract infections
• Intra-abdominal infections
• Pelvic infections
• Dental infections
• Endocarditis prophylaxis in penicillin-allergic patients

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines tailored to pediatric populations.

Adults: Refer to the appropriate prescribing guidelines for specific dosing based on the indication and severity of the infection.

Mechanism of action

Lindamycin exerts its antibacterial effects by binding to the 50S subunit of the bacterial ribosome, inhibiting peptide bond formation and thus interfering with protein synthesis. This action effectively halts bacterial growth and replication.

Pharmacodynamics

Lindamycin demonstrates time-dependent killing, where the duration of exposure above the minimum inhibitory concentration (MIC) correlates with its efficacy. The drug has a variable spectrum of activity, being effective against most gram-positive cocci, including Staphylococcus aureus (including some methicillin-resistant strains), and certain anaerobic bacteria, making it suitable for treating skin and soft tissue infections, respiratory tract infections, and some dental infections.

Pharmacokinetics

After oral administration, lindamycin is rapidly absorbed, with peak plasma concentrations occurring within 1 to 2 hours. It is extensively distributed in body tissues and fluids, including bones, and can cross the placenta. The drug is metabolized in the liver and has a half-life of approximately 2 to 3 hours. It is primarily excreted in the urine as metabolites, with less than 5% of the dose excreted unchanged.

Contra-indications

• Hypersensitivity to lincosamides or any component of the formulation
• History of gastrointestinal disease, particularly colitis
• Concurrent use with certain neuromuscular blocking agents

Adverse effects

• Gastrointestinal disturbances, including nausea, vomiting, diarrhea
• Rash or other allergic reactions
• Pseudomembranous colitis
• Hepatotoxicity
• Rarely, anaphylaxis or severe hypersensitivity reactions

Interactions

• May enhance the effects of neuromuscular blocking agents
• Clindamycin may reduce the efficacy of certain antibiotics, such as erythromycin
• Antacids may interfere with the absorption of clindamycin when taken orally

Precautions

• Use with caution in patients with a history of gastrointestinal disorders
• Monitor for signs of colitis, especially in patients with prolonged use
• Adjust dosage in patients with liver dysfunction
• Evaluate renal function in patients receiving prolonged therapy

Pregnancy

Clindamycin is classified as category B. Animal studies have not demonstrated any risk to the fetus, but adequate and well-controlled studies in pregnant women are lacking. Use only if clearly needed.

Breast-feeding

Clindamycin is excreted in breast milk. Caution should be exercised when administered to nursing mothers, and the infant should be monitored for gastrointestinal disturbances.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral capsules
• Oral solution
• Topical gel or cream
• Injectable solution